ABT Quote, Financials, Valuation and Earnings

Hologic, Inc. has a net margin of 15.5% compared to Abbott Laboratories's net margin of 17.09%. Abbott Laboratories's return on equity of 29.06% beat Hologic, Inc.'s return on equity of 11.09%.

Abbott Laboratories has a consensus price target of $133.11, signalling upside risk potential of 21.67%. On the other hand Hologic, Inc. has an analysts' consensus of $76.60 which suggests that it could grow by 2.49%. Given that Abbott Laboratories has higher upside potential than Hologic, Inc., analysts believe Abbott Laboratories is more attractive than Hologic, Inc..

Abbott Laboratories has a beta of 0.749, which suggesting that the stock is 25.138% less volatile than S&P 500. In comparison Hologic, Inc. has a beta of 0.717, suggesting its less volatile than the S&P 500 by 28.288%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.19%. Hologic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 64.34% of its earnings as a dividend. Hologic, Inc. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Hologic, Inc. quarterly revenues of $1B. Abbott Laboratories's net income of $1.8B is higher than Hologic, Inc.'s net income of $179.1M. Notably, Abbott Laboratories's price-to-earnings ratio is 29.54x while Hologic, Inc.'s PE ratio is 31.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.32x versus 4.09x for Hologic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.5% compared to Abbott Laboratories's net margin of 27.89%. Abbott Laboratories's return on equity of 29.06% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Abbott Laboratories has a consensus price target of $133.11, signalling upside risk potential of 21.67%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 23.17%. Given that Intuitive Surgical, Inc. has higher upside potential than Abbott Laboratories, analysts believe Intuitive Surgical, Inc. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.749, which suggesting that the stock is 25.138% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.19%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 64.34% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Abbott Laboratories's net income of $1.8B is higher than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Abbott Laboratories's price-to-earnings ratio is 29.54x while Intuitive Surgical, Inc.'s PE ratio is 63.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.32x versus 17.90x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 15.5% compared to Abbott Laboratories's net margin of 12.4%. Abbott Laboratories's return on equity of 29.06% beat Insulet Corp.'s return on equity of 18.92%.

Abbott Laboratories has a consensus price target of $133.11, signalling upside risk potential of 21.67%. On the other hand Insulet Corp. has an analysts' consensus of $370.44 which suggests that it could grow by 44.35%. Given that Insulet Corp. has higher upside potential than Abbott Laboratories, analysts believe Insulet Corp. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.749, which suggesting that the stock is 25.138% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.412, suggesting its more volatile than the S&P 500 by 41.175%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.19%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 64.34% of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Insulet Corp. quarterly revenues of $706.3M. Abbott Laboratories's net income of $1.8B is higher than Insulet Corp.'s net income of $87.6M. Notably, Abbott Laboratories's price-to-earnings ratio is 29.54x while Insulet Corp.'s PE ratio is 74.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.32x versus 7.36x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 15.5% compared to Abbott Laboratories's net margin of 11.84%. Abbott Laboratories's return on equity of 29.06% beat Stryker Corp.'s return on equity of 15.17%.

Abbott Laboratories has a consensus price target of $133.11, signalling upside risk potential of 21.67%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 15.28%. Given that Abbott Laboratories has higher upside potential than Stryker Corp., analysts believe Abbott Laboratories is more attractive than Stryker Corp..

Abbott Laboratories has a beta of 0.749, which suggesting that the stock is 25.138% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.19%. Stryker Corp. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.88 per share. Abbott Laboratories pays 64.34% of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Stryker Corp. quarterly revenues of $7.2B. Abbott Laboratories's net income of $1.8B is higher than Stryker Corp.'s net income of $849M. Notably, Abbott Laboratories's price-to-earnings ratio is 29.54x while Stryker Corp.'s PE ratio is 43.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.32x versus 5.67x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.